Pharmacokinetics of HIV therapies in pregnant patients: an update
- 19 April 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 16 (6), 449-461
- https://doi.org/10.1080/17425255.2020.1754792
Abstract
Introduction: Mother-to-child transmission (MTCT) of HIV is thought to account for over 90% of new paediatric infections, and is associated with poor maternal and foetal outcomes. As such ensuring further reduction in MTCT is a priority in HIV treatment and prevention programmes. Areas covered: This review aims to provide a comprehensive update on the pharmacokinetics of recently approved antiretroviral drugs and novel drug formulations and delivery systems. Alongside recent recommendations for dose adjustments, and an overview of the implications of co-infections on the pharmacokinetics of antiretrovirals relevant to pregnant HIV positive patients. Additionally, potential opportunities to progress pharmacokinetic research of new treatments in this population are highlighted. Expert opinion: In order to improve our understanding of how to provide safe and effective treatment to HIV positive pregnant women, further work is required to enable their inclusion in early stages of clinical trials. Incentives must be created for this research, in the form of additional investment by key stakeholders and regulatory agencies. Furthermore, as incidence of MTCT is reduced globally there is a need to conduct long-term pharmacovigilance studies in uninfected children exposed to HIV and antiretrovirals in utero, in order to determine the safest and most effective antiretroviral therapies.Keywords
This publication has 116 references indexed in Scilit:
- Pregnancy Incidence and Risk Factors among Women Participating in Vaginal Microbicide Trials for HIV Prevention: Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adultsJournal of Antimicrobial Chemotherapy, 2012
- Pregnancy-Related Effects on Lamivudine Pharmacokinetics in a Population Study with 228 WomenAntimicrobial Agents and Chemotherapy, 2012
- Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral FormulationAntimicrobial Agents and Chemotherapy, 2010
- Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymesExpert Opinion on Drug Metabolism & Toxicology, 2010
- Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant womenBritish Journal of Clinical Pharmacology, 2008
- Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol eliminationXenobiotica, 2008
- Angiotensin II Induces Soluble fms-Like Tyrosine Kinase-1 Release via Calcineurin Signaling Pathway in PregnancyCirculation Research, 2007
- Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancyAmerican Journal of Obstetrics and Gynecology, 2005
- SERIAL CHANGES IN RENAL HAEMODYNAMICS DURING NORMAL HUMAN PREGNANCYBJOG: An International Journal of Obstetrics and Gynaecology, 1981